Written and maintained by CASRAI Editorial Board
Last updated
Medical device regulatory affairs specialists, human factors engineers, and quality systems leads preparing a 510(k), De Novo, or Premarket Approval (PMA) submission rely on the FDA Human Factors guidance—formally titled Applying Human Factors and Usability Engineering to Medical Devices (issued February 3, 2016) alongside the FDA’s December 2022 draft guidance Content of Human Factors Information in Medical Device Marketing Submissions. Together with IEC 62366-1 and 21 CFR § 820.30 design controls, this framework defines how manufacturers must identify critical tasks, conduct a Use-Related Risk Analysis (URRA), and execute summative human factors validation testing across representative U.S. user groups.
What Is the FDA Human Factors Guidance?
The FDA Human Factors guidance is the Center for Devices and Radiological Health (CDRH) and Center for Biologics Evaluation and Research (CBER) regulatory framework governing how medical device user interfaces—spanning physical hardware controls, visual/auditory displays, software graphical user interfaces (GUIs), packaging, instructions for use (IFU), and user training—must be engineered and validated so that intended users in intended use environments can operate the device without serious use-related harm.
While the international standard IEC 62366-1:2015+AMD1:2020 establishes the general usability engineering lifecycle process, the FDA guidance sets specific regulatory expectations for U.S. marketing submissions, including:
- An explicit severity-driven definition of a critical task that includes compromised medical care.
- Application of the Perception, Cognition, and Action (PCA) cognitive task model to analyze use errors.
- A strict hierarchy of risk control measures that prioritizes inherent design safety over labeling or training.
- A quantitative sample-size expectation of at least 15 representative U.S. participants per distinct user group for summative human factors validation testing.
- A standardized 8-section HFE/UE Report structure stored in the Design History File (DHF) and submitted to the agency.
Critical Tasks and the Perception–Cognition–Action (PCA) Analytical Model
Every evaluation under the FDA Human Factors guidance hinges on how the manufacturer defines and identifies critical tasks during its Use-Related Risk Analysis (URRA), which links usability engineering directly to the ISO 14971 risk management file.
1. FDA Definition of a Critical Task
The FDA defines a critical task as a user task which, if performed incorrectly or not performed at all, would or could cause serious harm to the patient or user, where harm is defined to include compromised medical care. Crucially, the FDA identifies critical tasks based on the severity of potential harm alone, independent of the estimated probability or frequency of the use error occurring.
2. Decomposing Tasks via Perception, Cognition, and Action (PCA)
To uncover potential use errors systematically, the FDA guidance directs engineers to evaluate every user interaction across three sequential stages:
- Perception (P): How the user senses visual, auditory, or tactile signals from the device, display, packaging, or environment (e.g., reading a syringe barrel graduation in a dimly lit ICU room or hearing an infusion occlusion alarm over ambient hospital noise).
- Cognition (C): How the user interprets perceived information, recalls training or clinical knowledge, and makes a decision (e.g., calculating a weight-based infusion rate or interpreting an ambiguous software warning code).
- Action (A): How the user executes the physical or manual step on the device interface (e.g., depressing an autoinjector with sufficient force for 10 seconds, priming fluid tubing to purge air, or tapping a capacitive touchscreen while wearing sterile surgical gloves).
3. The FDA Risk Control Priority Hierarchy
When a URRA identifies a use-related hazard associated with a critical task, the FDA requires manufacturers to apply risk mitigations in strict descending order of effectiveness:
- Inherent Safety by Design (Highest Priority): Redesigning the physical or software user interface so the use error cannot occur (for example, engineering physically non-interchangeable luer/enteral connectors under ISO 80369 or eliminating an ambiguous multi-step calibration menu).
- Protective Measures in the Device or System: Adding automated physical guards, software interlocks, or prominent confirmation alarms that prevent a slip or mistake from resulting in patient harm.
- Information for Safety / Labeling and Training (Lowest Priority): Adding warnings to the IFU, on-device labels, or user training modules. The FDA explicitly warns reviewers not to accept “revising the IFU” or “re-training users” as the primary mitigation when a physical or software interface redesign is feasible.
Formative Evaluations vs. Summative Human Factors Validation Testing (The 15-Participant Rule)
The FDA distinguishes sharply between iterative formative usability evaluations conducted during design development and the final human factors validation (summative) test conducted on production-equivalent units.
| Testing Parameter | Formative Usability Evaluation (Section 5) | Human Factors Validation / Summative Testing (Section 8) |
|---|---|---|
| Primary Objective | Explore user interface concepts, identify unanticipated use errors early, and refine hardware/software/IFU design iteratively. | Demonstrate conclusively that representative intended users can perform all critical tasks safely and effectively under simulated (or actual) use conditions. |
| Device Maturity | Early prototypes, wireframes, 3D-printed models, or pre-production builds. | Final, production-equivalent device hardware, software, packaging, and final IFU/labeling. |
| Participant Sample Size | Typically 5 to 8 participants per iteration; flexible based on design learning goals. | Minimum of 15 representative U.S. participants per distinct user group (e.g., 15 lay patients + 15 clinical nurses = 30 total participants). |
| Training & Decay Interval | Can test untrained walkthroughs or prototype training materials immediately. | Must match realistic commercial training; if training is provided, FDA typically expects a training decay interval (e.g., 1 hour to several days) between training and validation testing. |
| Data Collected & Follow-Up | Observational notes and design modification feedback. | Complete capture of all use errors, close calls, and operational difficulties on every critical task, followed by structured subjective debriefing to determine the root cause of every observed failure. |
Why 15 Participants per User Group? Based on binomial probability modeling referenced in the FDA guidance (Faulkner, 2003), testing 15 representative participants from a homogeneous user group provides at least a 90%–97% probability of observing at least one instance of a usability problem that has a true population occurrence rate of 10%–20%. When two user groups interact with the device differently—or have distinct baseline clinical knowledge, such as adolescent lay users versus pediatric endocrinology nurses—each distinct group requires its own cohort of at least 15 U.S. residents.
The 8 Required Sections of an FDA HFE/UE Report and Submission Categories (1, 2, and 3)
Under the 2016 Final Guidance and the December 2022 Draft Guidance (Content of Human Factors Information in Medical Device Marketing Submissions), the complete HFE/UE Report is organized into eight numbered sections, and the required submission subset is determined by a three-tier risk decision tree:
| HFE/UE Report Section | Required Technical Content | Cat 1 (No Critical Task Impact) | Cat 2 (Modified Device, No New/Changed Critical Tasks) | Cat 3 (New Device or New/Modified Critical Tasks) |
|---|---|---|---|---|
| Section 1: Conclusion & High-Level Summary | Compliance statement confirming that the device interface has been found safe and effective for intended users, uses, and use environments, plus rationale for the submission category. | Required | Required | Required |
| Section 2: Intended Users, Uses, Environments & Training | Demographic/physical/cognitive characteristics of each user group, clinical indication, lighting/noise/sterility of the use environment, and commercial training model. | Not submitted (held in DHF) | Required | Required |
| Section 3: Description of Device User Interface | Annotated photographs, engineering drawings, software screen maps, and IFU/packaging layout (plus comparison table of changes for modified devices). | Not submitted (held in DHF) | Required | Required |
| Section 4: Summary of Known Use Problems | Analysis of FDA MAUDE adverse event reports, recalls, literature, and complaints for predicate or similar devices. | Not submitted (held in DHF) | Required | Required |
| Section 5: Summary of Preliminary (Formative) Evaluations | Key findings from cognitive walkthroughs, heuristic analyses, and formative usability tests, showing how early use errors drove interface redesigns. | Not submitted (held in DHF) | Not submitted (held in DHF) | Required |
| Section 6: Analysis of Hazards and Risks (URRA) | Complete Use-Related Risk Analysis table mapping tasks, potential use errors (PCA), clinical hazards, severity of harm, risk controls, and verification methods. | Not submitted (held in DHF) | Required | Required |
| Section 7: Identification & Description of Critical Tasks | Explicit severity threshold definition and complete inventory of all critical tasks and task sequences. | Not submitted (held in DHF) | Required | Required |
| Section 8: Human Factors Validation Testing of Final Design | Summative protocol, participant demographics (≥15 per group), task performance results, root-cause analysis of every use error/close call/difficulty, and residual risk justification. | Not submitted (held in DHF) | Not submitted (held in DHF) | Required |
Before locking the summative validation protocol for a Category 3 submission (especially for combination products such as autoinjectors, home dialysis machines, infusion pumps, or reprocessing instructions), sponsors frequently submit their URRA, critical task list, and draft summative protocol to CDRH via the FDA Q-Submission (Pre-Sub) Program to confirm agency alignment on user group definitions and sample sizes.
Frequently Asked Questions
What is the FDA Human Factors guidance?
The FDA Human Factors guidance (‘Applying Human Factors and Usability Engineering to Medical Devices’, issued February 2016, supplemented by the December 2022 draft submission guidance) sets CDRH and CBER expectations for designing and validating medical device user interfaces. It requires manufacturers to conduct a Use-Related Risk Analysis (URRA), identify critical tasks, prioritize inherent design safety over labeling, and validate the final device with representative U.S. users.
How many participants are required for FDA human factors validation testing?
The FDA recommends a minimum of 15 representative U.S. participants per distinct intended user group for summative (human factors validation) testing. If a device has multiple distinct user groups that perform different tasks or have different knowledge levels (for example, lay patients, lay caregivers, and healthcare professionals), each group requires at least 15 participants.
What is a critical task under FDA human factors guidance?
A critical task is any user task which, if performed incorrectly or not performed at all, would or could cause serious harm to the patient or user, where harm is defined to include compromised medical care. Critical tasks are identified solely by the severity of potential harm in the Use-Related Risk Analysis (URRA), regardless of estimated error probability.
